Sanofi Agreement was Nurix Therapeutics’s largest revenue line in fiscal 2025, bringing in $30.00M of $55.70M (54%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 | FY 2023 | FY 2023 | FY 2025 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|
| Gilead Agreement | $23.70M | $20.00M | $29.90M | — | — | — |
| Sanofi Agreement | $15.00M | — | $25.40M | $15.00M | $15.00M | $30.00M |
| Pfizer | — | — | $1.70M | — | — | $25.70M |
| Total | $38.70M | $20.00M | $57.00M | $15.00M | $15.00M | $55.70M |
Nurix Therapeutics brought in $55.70M from its two revenue lines in fiscal 2025, the year ended November 30, 2025. That is less than the $83.98M it reports by product and service, so these revenue lines do not cover all of its revenue. Sanofi Agreement was the largest at $30.00M (53.9%), ahead of Pfizer at $25.70M (46.1%).
Nurix Therapeutics began breaking out Pfizer in fiscal 2023, when it brought in $1.70M. Nurix Therapeutics stopped reporting Gilead Agreement as a separate revenue line after fiscal 2023, when it brought in $29.90M.
Collaboration Revenue was Nurix Therapeutics’s largest product and service line in fiscal 2025, bringing in $53.98M of $83.98M (64%).
| Product and Service | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $38.63M | — | $56.99M | $54.55M | — | — | $53.98M |
| License Revenue | — | $20.00M | $20.00M | — | $15.00M | $15.00M | $30.00M |
| Total | $38.63M | $20.00M | $76.99M | $54.55M | $15.00M | $15.00M | $83.98M |
Nurix Therapeutics brought in $83.98M from its two product and service lines in fiscal 2025, the year ended November 30, 2025. Nurix Therapeutics regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $15.00M. Collaboration Revenue was the largest at $53.98M (64.3%), ahead of License Revenue at $30.00M (35.7%).
Nurix Therapeutics began breaking out License Revenue in fiscal 2023, when it brought in $20.00M.
Nurix Therapeutics (NRIX) reports its revenue by collaborative arrangement and arrangement other than collaborative and by product and service. In fiscal 2025, Sanofi Agreement was its largest revenue line, bringing in $30.00M (53.9% of the total), followed by Pfizer at $25.70M (46.1%).
Sanofi Agreement was Nurix Therapeutics' largest revenue line in fiscal 2025, bringing in $30.00M, or 53.9% of the $55.70M total across its two revenue lines.
Collaboration Revenue was Nurix Therapeutics' largest product and service line in fiscal 2025, bringing in $53.98M, or 64.3% of the $83.98M total across its two product and service lines.
Every figure comes from Nurix Therapeutics' annual financial filings, as reported. Each line keeps the name Nurix Therapeutics gives it, and years follow its fiscal calendar.
Nurix Therapeutics' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.